Potent P2Y₁₂ inhibitors in patients with acute myocardial infarction and cardiogenic shock.

ABSTRACT:

Background

Although potent P2Y₁₂ inhibitors, such as ticagrelor and prasugrel, are standard treatment in patients with acute myocardial infarction (AMI), evidence for their efficacy and safety compared with clopidogrel is limited in patients with AMI complicated by cardiogenic shock.

Methods

Among 28,949 patients from the nationwide pooled registry of KAMIR-NIH and KAMIR-V, a total of 1482 patients (5.1%) with AMI and cardiogenic shock who underwent percutaneous coronary intervention of the culprit vessel were selected. Primary outcome was major adverse cardiovascular event (MACE, a composite of cardiac death, MI, repeat revascularization and definite stent thrombosis) and major secondary outcome was Bleeding Academic Research Consortium (BARC) type 2 or greater b

SUBMITTER: Jo J 

PROVIDER: S-EPMC11800629 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature